These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

983 related items for PubMed ID: 18204174

  • 1. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G, Brand P, Meyer T, Herpich C, Müllinger B, Brom J, Weidinger G, Kohlhäufl M, Häussinger K, Spannagl M, Schramm W, Siekmeier R.
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [Abstract] [Full Text] [Related]

  • 2. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 3. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F.
    Thromb Haemost; 1988 Jun 16; 59(3):388-91. PubMed ID: 2847348
    [Abstract] [Full Text] [Related]

  • 4. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May 16; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

  • 5. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P, Kiehl R, von Blohn G, Köhler M, Meierhenrich U, Wenzel E.
    Thromb Haemost; 1986 Oct 21; 56(2):225-8. PubMed ID: 3810557
    [Abstract] [Full Text] [Related]

  • 6. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul 21; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 7. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P, Reynaud J, Tardy-Ponce B, Laporte-Simitsidis S, Scully M, Goodwyn C, Queneau P, Decousus H.
    Thromb Haemost; 1995 Aug 21; 74(2):660-6. PubMed ID: 8585003
    [Abstract] [Full Text] [Related]

  • 8. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Aug 21; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]

  • 9. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).
    Dettori AG, Tagliaferri A, Dall'Aglio E, Pini M.
    Int Angiol; 1988 Aug 21; 7(3 Suppl):7-18. PubMed ID: 2850327
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H.
    J Clin Pharmacol; 2008 Oct 21; 48(10):1189-96. PubMed ID: 18716314
    [Abstract] [Full Text] [Related]

  • 11. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M, Veyssier-Belot C, Alhenc-Gelas M, Chatellier G, Billaud-Mesguish E, Fiessinger JN, Aiach M.
    Br J Clin Pharmacol; 1995 Dec 21; 40(6):577-84. PubMed ID: 8703665
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sié P.
    Thromb Haemost; 1998 Feb 21; 79(2):338-41. PubMed ID: 9493587
    [Abstract] [Full Text] [Related]

  • 13. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G, Salanitri G, Catania G.
    Drugs Exp Clin Res; 1988 Feb 21; 14(6):423-7. PubMed ID: 2850903
    [Abstract] [Full Text] [Related]

  • 14. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 21; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
    Imberti D, Legnani C, Baldini E, Cini M, Nicolini A, Guerra M, De Paoli M, Zanardi A, Palareti G.
    Thromb Res; 2009 Dec 21; 124(6):667-71. PubMed ID: 19482341
    [Abstract] [Full Text] [Related]

  • 16. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
    Millet J, Jouault SC, Mauray S, Theveniaux J, Sternberg C, Boisson Vidal C, Fischer AM.
    Thromb Haemost; 1999 Mar 21; 81(3):391-5. PubMed ID: 10102467
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y.
    Thromb Haemost; 1995 Nov 21; 74(5):1286-92. PubMed ID: 8607111
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B.
    Thromb Haemost; 1995 Mar 21; 73(3):398-401. PubMed ID: 7667822
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y.
    Am J Kidney Dis; 2008 May 21; 51(5):789-95. PubMed ID: 18436089
    [Abstract] [Full Text] [Related]

  • 20. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dünser MW.
    Crit Care; 2005 Oct 05; 9(5):R541-8. PubMed ID: 16277716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.